BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Sold by Lbp Am Sa

LBP AM SA decreased its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 67.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,449 shares of the biotechnology company's stock after selling 11,237 shares during the quarter. LBP AM SA's holdings in BioMarin Pharmaceutical were worth $358,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in BMRN. Erste Asset Management GmbH bought a new stake in BioMarin Pharmaceutical during the third quarter valued at about $48,527,000. Assenagon Asset Management S.A. boosted its position in BioMarin Pharmaceutical by 461.3% during the fourth quarter. Assenagon Asset Management S.A. now owns 611,667 shares of the biotechnology company's stock valued at $40,205,000 after purchasing an additional 502,695 shares in the last quarter. Vestal Point Capital LP bought a new stake in BioMarin Pharmaceutical during the third quarter valued at about $28,116,000. Clearline Capital LP bought a new stake in BioMarin Pharmaceutical during the third quarter valued at about $22,477,000. Finally, Bellevue Group AG boosted its position in BioMarin Pharmaceutical by 533.7% during the third quarter. Bellevue Group AG now owns 330,976 shares of the biotechnology company's stock valued at $23,264,000 after purchasing an additional 278,744 shares in the last quarter. Institutional investors own 98.71% of the company's stock.

BioMarin Pharmaceutical Price Performance

BMRN traded up $0.28 during trading on Thursday, hitting $71.60. The company's stock had a trading volume of 1,355,711 shares, compared to its average volume of 1,541,757. The company has a current ratio of 5.33, a quick ratio of 2.62 and a debt-to-equity ratio of 0.11. BioMarin Pharmaceutical Inc. has a twelve month low of $60.63 and a twelve month high of $94.85. The business's fifty day simple moving average is $66.44 and its 200 day simple moving average is $68.40. The firm has a market capitalization of $13.66 billion, a price-to-earnings ratio of 32.55, a P/E/G ratio of 0.61 and a beta of 0.33.

Remove Ads

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last issued its quarterly earnings data on Wednesday, February 19th. The biotechnology company reported $0.72 EPS for the quarter, beating the consensus estimate of $0.54 by $0.18. The company had revenue of $747.31 million for the quarter, compared to analyst estimates of $711.05 million. BioMarin Pharmaceutical had a return on equity of 9.91% and a net margin of 14.96%. On average, equities research analysts forecast that BioMarin Pharmaceutical Inc. will post 3.15 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on BMRN. UBS Group raised their price objective on BioMarin Pharmaceutical from $109.00 to $113.00 and gave the company a "buy" rating in a research report on Thursday, February 20th. Royal Bank of Canada reissued a "sector perform" rating and issued a $70.00 price target on shares of BioMarin Pharmaceutical in a report on Thursday, February 20th. Piper Sandler raised their price target on BioMarin Pharmaceutical from $122.00 to $126.00 and gave the stock an "overweight" rating in a report on Thursday, February 20th. Cantor Fitzgerald reissued an "overweight" rating and issued a $90.00 price target on shares of BioMarin Pharmaceutical in a report on Thursday, February 20th. Finally, Bank of America raised their price target on BioMarin Pharmaceutical from $99.00 to $103.00 and gave the stock a "buy" rating in a report on Thursday, February 20th. Seven analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, BioMarin Pharmaceutical has a consensus rating of "Moderate Buy" and a consensus price target of $94.00.

Insider Transactions at BioMarin Pharmaceutical

In other news, CAO Erin Burkhart sold 1,344 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $68.38, for a total value of $91,902.72. Following the sale, the chief accounting officer now directly owns 13,105 shares of the company's stock, valued at $896,119.90. The trade was a 9.30 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 1.85% of the company's stock.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.